Suppr超能文献

经常使用皮质类固醇和少量使用短效β2激动剂可减少哮喘住院率。

Regular use of corticosteroids and low use of short-acting beta2-agonists can reduce asthma hospitalization.

作者信息

Senthilselvan Ambikaipakan, Lawson Joshua A, Rennie Donna C, Dosman James A

机构信息

Department of Public Health Sciences, University of Alberta, 13-106B Clinical Sciences Building, Edmonton, AL, Canada, T6G 2G3.

出版信息

Chest. 2005 Apr;127(4):1242-51. doi: 10.1378/chest.127.4.1242.

Abstract

OBJECTIVES

Inhaled corticosteroids (ICS) and inhaled short-acting beta(2)-agonists (ISABA) are the most commonly used medications for management of asthma. Increased asthma morbidity and mortality have been reported with excess use of ISABA in several studies. In these studies, authors have used different indicators to control for the potential confounding by asthma severity. The objective of this study was to determine the effect of ICS use on the association between use of ISABA and first hospitalization for asthma after controlling for several indicators of asthma severity.

DESIGN

An inceptional cohort study using Saskatchewan Health databases.

SETTING

The Province of Saskatchewan, Canada.

PARTICIPANTS

A total of 29,957 persons aged 5 to 54 years who had at least five asthma-related visits to physicians between 1991 and 2000.

RESULTS

Among the subjects with increased asthma severity, indicated by one or more average number of asthma-related physician visits per 3 months during the follow-up, high use of ISABA was a risk factor for hospitalization when no ICS were used (rate ratio [RR], 2.16; 95% confidence interval [CI], 1.51 to 2.95). There was a beneficial effect of ISABA when there was low use of ICS (RR, 0.65; 95% CI, 0.42 to 0.93) or high use of ICS (RR, 0.23; 95% CI, 0.12 to 0.41). Among the subjects with less severe asthma, indicated by less than one asthma-related physician visits per 3 months, on average, during the follow-up, the risk of hospitalization was even greater for high use of ISABA when no ICS were used (RR, 10.06; 95% CI, 6.99 to 14.47). This was reduced but not abolished when there was low use of ICS (RR, 3.24; 95% CI, 2.29 to 4.59) and negated altogether by high use of ICS (RR, 1.10; 95% CI, 0.39 to 3.12).

CONCLUSION

Among both severe and less severe asthma groups, high use of ISABA was associated with an increased risk of asthma hospitalization in the absence of any use of ICS, which was progressively reduced with low and high use of ICS. This finding was independent of asthma severity and could result from lack of control through over reliance on ISABA in asthma management.

摘要

目的

吸入性糖皮质激素(ICS)和吸入性短效β2受体激动剂(ISABA)是治疗哮喘最常用的药物。多项研究报告称,过度使用ISABA会增加哮喘的发病率和死亡率。在这些研究中,作者使用了不同的指标来控制哮喘严重程度可能造成的混杂影响。本研究的目的是在控制了几个哮喘严重程度指标后,确定使用ICS对ISABA使用与首次因哮喘住院之间关联的影响。

设计

一项使用萨斯喀彻温省卫生数据库的队列起始研究。

地点

加拿大萨斯喀彻温省。

参与者

共有29957名年龄在5至54岁之间的人,他们在1991年至2000年期间至少有5次与哮喘相关的就诊记录。

结果

在随访期间,以每3个月哮喘相关就诊的平均次数一个或更多来表明哮喘严重程度增加的受试者中,当未使用ICS时,高剂量使用ISABA是住院的危险因素(率比[RR],2.16;95%置信区间[CI],1.51至2.95)。当低剂量使用ICS(RR,0.65;95%CI,0.42至0.93)或高剂量使用ICS(RR,0.23;95%CI,0.12至0.41)时,ISABA有有益作用。在随访期间平均每3个月哮喘相关就诊次数少于1次来表明哮喘不太严重的受试者中,当未使用ICS时,高剂量使用ISABA的住院风险更高(RR,10.06;95%CI,6.99至14.47)。当低剂量使用ICS时,这种风险降低但未消除(RR,3.24;95%CI,2.29至4.59),而高剂量使用ICS则完全消除了这种风险(RR,1.10;95%CI,0.39至3.12)。

结论

在重度和轻度哮喘组中,在未使用任何ICS的情况下,高剂量使用ISABA与哮喘住院风险增加相关,随着低剂量和高剂量使用ICS,这种风险逐渐降低。这一发现与哮喘严重程度无关,可能是由于在哮喘管理中过度依赖ISABA而缺乏控制所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验